Saroglitazar

Saroglitazar is a synthetic small molecule that acts as a dual agonist of the peroxisome proliferator-activated receptors, or PPARs, targeting both the alpha and gamma subtypes, and it belongs to the drug class known as glitazars ^[3]. PPARs are nuclear receptors that regulate genes governing lipid and glucose metabolism, and dual PPAR-alpha/gamma activation is intended to combine the triglyceride-lowering effect of PPAR-alpha with the insulin-sensitizing effect of PPAR-gamma ^[3]. It is taken by mouth, is highly bound to plasma proteins, and is metabolized in the liver ^[3].

The drug was developed by Zydus (Cadila Healthcare) and became the first glitazar to reach the market, approved by the Drug Controller General of India in 2013 for diabetic dyslipidemia and later for additional indications ^[1][3]. It is marketed in India under the brand names Lipaglyn and Bilypsa, and although widely used there, it has not been approved in the United States or Europe ^[3]. Earlier drugs in the glitazar class had been abandoned during development because of safety problems, which made careful evaluation of saroglitazar important ^[3].

In a Phase III trial, saroglitazar substantially lowered plasma triglycerides in patients with type 2 diabetes and hypertriglyceridemia that was not controlled by statin therapy, and it also improved other lipid parameters and fasting glucose ^[1]. Because non-alcoholic fatty liver disease (NAFLD) is closely tied to insulin resistance and abnormal lipids, the drug has been studied in that setting; a randomized, placebo-controlled Phase 2 trial found that it reduced liver enzyme levels, liver fat content, insulin resistance, and atherogenic dyslipidemia in patients with NAFLD and non-alcoholic steatohepatitis ^[2]. Observational studies in patients with diabetes and NAFLD have reported reductions in liver stiffness and in glycemic and lipid measures, and the drug has also been explored for primary biliary cholangitis ^[3][4].

Saroglitazar is supplied as oral tablets ^[1]. Its regulatory status is largely limited to India and a few other countries, and it remains an investigational agent in major Western markets, where long-term cardiovascular outcome data are still lacking ^[3].

In clinical studies to date, saroglitazar has generally been well tolerated, with no major serious adverse events attributed to it, although reported effects include gastrointestinal complaints, weakness, dizziness, and modest changes in liver or kidney laboratory values ^[1][2]. As with other PPAR-gamma agonists, some weight gain can occur, and the long-term cardiovascular safety of the drug has not been fully established ^[2][3].

Saroglitazar is prescription only and is generally well tolerated in the trials done so far. Reported effects are usually mild and include weakness, stomach discomfort, gastritis, dizziness, and occasional small rises in liver enzymes. Unlike older glitazones it shows little of the weight gain, swelling, or heart failure signal, though long-term global safety data remain limited. Liver function should be checked before and during treatment, and it is avoided in significant liver impairment. It has not been studied in pregnancy, breastfeeding, or children, so those groups should not use it. Because the worldwide evidence base is smaller than for statins or fibrates, prescribers weigh it as a regionally established option rather than a globally validated one.

Saroglitazar was discovered and developed in India by Zydus Cadila (Cadila Healthcare), which pursued a dual peroxisome proliferator-activated receptor agonist deliberately weighted toward PPAR-alpha to capture lipid and glucose benefits while limiting the fluid retention and weight gain that had troubled earlier glitazars. It was approved by the Drug Controller General of India in 2013 for diabetic dyslipidemia and hypertriglyceridemia, marketed as Lipaglyn, and is often cited as the first new drug fully discovered and developed within India. This was a notable achievement given that several other glitazars had been abandoned during development for safety concerns. In 2020, Indian regulators additionally approved it for non-alcoholic steatohepatitis, and it has since been studied in fatty liver disease and related metabolic conditions.

Saroglitazar stands out as the first glitazar to reach clinical use anywhere, having succeeded where several earlier dual PPAR agonists failed, and it carries symbolic weight as a landmark of indigenous Indian drug discovery. It has a solid record for lowering blood triglycerides and improving the lipid profile in diabetic dyslipidemia, while also improving insulin sensitivity and blood sugar. Its dual mechanism has made it a candidate of genuine interest for non-alcoholic fatty liver disease and steatohepatitis, an area of high unmet need, and early trials have been encouraging on markers of liver fat and inflammation. In balanced terms, much of its clinical experience comes from India, and large long-term cardiovascular outcome data remain limited, so its broader place in therapy is still being defined.